Media

Media

Media

Recent News

News Provided By PhotonMD, Inc
Posted On July 06, 2017, 10:00 ET

MORRISVILLE, N.C., July 6, 2017 /PRNewswire/ – PhotonMDTM, Inc. an innovator in photomedicine devices, announced today that Robert Catlin IV has joined the Company as Senior Director of Marketing to further develop their growing photomedicine device business and lead the commercial efforts. Rob is an award-winning marketing and sales leader in the medical device and pharmaceutical industries. Joining in advance of the launch of PhotonMD’s new direct to consumer aesthetic product, Rob will continue his impact on the health and well-being of people’s lives.

Rob brings with him nearly 2 decades of experience developing and executing strategic business plans for market leading medical devices. He will be responsible for PhotonMD’s physician and consumer relationship building and rapidly increasing market penetration and brand awareness in the consumer aesthetic marketplace.

“Rob’s medical device and market experience uniquely positions him to lead the commercial strategy of PhotonMD as we continue to develop and drive to our goal of transforming lives through photomedicine. With a proven track record for successfully leading large scale initiatives and driving innovation, Rob’s leadership skills and experience executing strategic visions are well suited to lead PhotonMD’s commercial efforts that will drive us to be a leader in our industry,” said Dr. Nick Medendorp, Jr., President and CEO of PhotonMD.

Most recently, Rob was Sr. Director of Marketing for Merz Aesthetics Devices. There, he enhanced new product development, created all consumer and physician marketing campaigns for the Cellfina® System, and delivered category leadership within six months of launch. Rob contributed to overall revenue growth and won five awards for his efforts, including Allure’s 2015, “Best of Beauty Breakthrough”.

While Medendorp declined to discuss the specifics of the product at this point, he said it involves a safer form of light therapy for an aesthetic application.

“I am thrilled to join the PhotonMD team. I believe the potential for growth and value creation is tremendous, given the talented and passionate people at PhotonMD. Having played leadership roles in similar business situations and industries, I am confident that we can execute the commercial plans to drive consistent sales and margin growth. I look forward to becoming part of the PhotonMD family and partnering with the team to build the business,” said Catlin.

In addition to his prior business development and sales growth experience, Rob has extensive experience with successfully executing consumer, professional and new product launches to drive revenue and increase market share. Before working for Merz, Rob was the director of marketing for Medicis Pharmaceutical’s Restylane® family of products. Prior to that, he managed the southeast sales team for Medicis and was a brand manager for Allergan Medical. One of Rob’s key accomplishments in the industry was developing and implementing the Allergan Partner Privileges Program, a hallmark physician loyalty program currently used by Allergan. In 2016, Rob was counted among Aesthetic Everything’s Top 10 Company Executives.

Catlin holds a B.S. in Finance and Marketing from Florida State University and an M.B.A from the University of Southern California.

About PhotonMD

PhotonMD ’s Modulated Light TherapyTM technology is based on a photomedicine platform that can be delivered in a variety of doses and tailored form factors for specific indications. For more information, please visit www.PhotonMD.com.

Forward-looking Statements

Except for historical information, all the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: reliance on key personnel; the early stage of our business; risks associated with the medical device and drug development processes; competition; and other risks described in other Company press releases and presentations. PhotonMD assumes no obligation and do not intend to update these forward-looking statements, except as required by law.

SOURCE PhotonMD, Inc.
Contact
Rob Catlin : rcatlin@photonmd.com
T: (919) 229-4642

News Provided By KNOW Bio, LLC
Posted On Mar. 9, 2017, 10:00 ET

DURHAM, N.C., Mar. 9, 2017 /PRNewswire/ — KNOW Bio, LLC.  a leading innovator in healthcare, today announced the debut of PhotonMD, Inc. their new medical device business. It is led by Dr. Nicholas Medendorp, Jr, who serves as President and Chief Executive Officer. Medendorp, founder of PhotonMD, is a seasoned technology and product development leader with more than 80 US patents in LED and lighting products. He has more than 19 years of experience in the technology development industry and has served in a broad range of functions, including electro-optics, product development, manufacturing and marketing. In addition, he has extensive experience in developing companies to high growth and profitability, including senior leadership roles with start-ups and large technology companies.

“Nick Medendorp brings a very diverse technology knowledge base and is highly skilled at building strong teams. Nick’s passion and tenacity are positioning PhotonMD as a dominant player in the photomedicine device market,” said Neal Hunter, Chairman of KNOW Bio. Most recently, Medendorp served as Vice President, Medical Devices at Novan, Inc (NASDAQ: NOVN) where he led the team responsible for the creation and development of medical devices. This group, which was the foundation for PhotonMD , was included in the separation of assets in late 2015 prior to Novan taking the medical dermatology business public. Previously, Nick served as Vice President of Research and Development and Vice President of Operations at Cree, Inc. where he focused on building teams that accelerated LED technology development and deployment in commercial and industrial applications.

“I am proud of the world class team we have assembled that has more than 65 years of product development experience, medical device commercialization, and has been involved in more than 50 device clearances. I look forward to our team accelerating recent advancements in the understanding of the biological responses to light and improvements in the digitization and selectivity of light-based technologies,” Medendorp said.

About PhotonMD

PhotonMD ’s Modulated Light TherapyTM technology is based on a photomedicine platform that can be delivered in a variety of doses and tailored form factors for specific indications. KNOW Bio, LLC was created to develop and optimize biotechnology solutions for many different applications. For more information, please visit www.photonmd.com.

Forward-looking Statements

Except for historical information, all the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: reliance on key personnel; the early stage of our business; risks associated with the medical device and drug development processes; competition; and other risks described in other Company press releases and presentations. KNOW Bio and PhotonMD assumes no obligation and do not intend to update these forward-looking statements, except as required by law.
Source: KNOW Bio, LLC.
Contact
Ray Young: ray@razorsharppr.com
T: (512) 633-6855

News Provided By KNOW Bio, LLC
Posted On Mar. 10, 2017, 2:19pm EST

Durham-based medical device company PhotonMD –focused on light therapy –is looking to take its first product to market later this year, according to President and CEO Dr. Nicholas Medendorp Jr.

PhotonMD started in January 2016 after separating from Novan (Nasdaq: NOVN) – which is developing a treatment for acne without the use of antibiotics – prior to its initial public offering. Novan’s IPO closed in September and raised $51.9 million, before underwriters’ discounts and commissions.

Novan was focused on medical dermatology and “the light-based medical devices did not really fit that asset class,” says Medendorp. Ultimately, PhotonMD was spun out as a portfolio company of KNOW Bio, which has “additional IP assets” it is planning to take to market.

He says that PhotonMD is preparing for its 510(K) premarket submission to the U.S. Food and Drug Administration for its first product next quarter. The product will “likely be cleared in the second half of 2017,” he says and also “available to the marketplace,” later this year.

While Medendorp declined to discuss the specifics of the product at this point, he said it involves a safer form of light therapy for an aesthetic application.

Medendorp previously served as vice president of medical devices at Novan, and prior to that, served as vice president of research and development as well as vice president of operations at Cree.

F. Neal Hunter, founder and former CEO of Cree, is among Novan’s largest shareholders. He also serves as chairman of KNOW Bio.

Medendorp says that PhotonMD will be “leveraging technology for other indications” as well and that the company currently consists of eight full-time employees. We “have a hiring plan [and] we’ll likely double the size of the company in the next 12 months,” he says.

In terms of its commercialization plan and additional assets, Medendorp says PhotonMD “will be raising additional capital in the future.” He declined to comment further on funding.

The company has office space at Keystone Technology Park.